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Background and Objective. Daily folic acid intake, prior to conception and in early pregnancy, signiﬁcantly reduces neural tube
defects (NTDs). We compared folic acid consumption among Jewish and Bedouin women and the recommendations of family
physicians and gynecologists. Methods. We compared 64 Muslim Bedouin women and 65 Jewish women. We also compared
39 gynecologists and 60 family physicians. Results. Fifty-one Jewish women (78.5%) took folic acid during pregnancy, but only
seven (10.8%) before conception. Sixty Bedouin women (93.75%) took folic acid during pregnancy, but only four (6.25%)
before conception (P<. 05). Five Jewish women (7.7%) and two Bedouin women (3.1%) took folic acid three months before
conception. Thirty-three gynecologists (87%) recommend preconception folic acid compared with thirty-six family physicians
(60%) (P<. 05). Conclusions. The majority of women use folic acid during pregnancy, but only few do so to prevent NTDs. There
is a signiﬁcant diﬀerence between doctors’ recommendations and actual practice.
1.Introduction
Neural tube defects (NTDs), including spina biﬁda, anen-
cephaly, and encephalocele, are among the most common
birth defects and cause morbidity and mortality among
fetuses and babies [1].
The incidence of NTDs in the United States is approxi-
mately one per 1,000 pregnancies. Approximately one third
of 4,000 pregnancies with NTDs end with spontaneous
or induced abortion, so there are about 2,500 live births
with NTD annually in the US [2]. There is a signiﬁcant
geographical variation in the rate of NTDs [3]. In the years
1999-2000 there were at least 394 cases of isolated NTD
in Israel, with a nearly fourfold incidence among non-Jews
compared to Jews [4].
The embryonic basis of NTD is not fully understood, but
a common abnormality is lack of closure of the neural tube
[3]. The normal development and closure of the neural tube
are completed by the 25th day after fertilization.
The mortality rate among newborns with spina biﬁda
is 10% in the United States, but nearly 100% in China [3].
Among surviving babies there is a high rate of neurological
complications such as paralysis, hydrocephalus, Arnold
Chiari type II and syringomyelia [3]. The known risk factors
for the development of NTD are low socioeconomical class,
maternal diabetes, antiepileptic drugs, fever in the early stage
of pregnancy, and obesity [3].
In families with a history of NTD, there is a 2%-3%
risk of NTD in future pregnancies. The association between
folic acid supplementation and reduced rates of NTD is
well established [5]. A study among 130,142 Chinese women
between 1993–1995 demonstrated a reduction in the risk for
NTD of up to 85% in women who took 0.4mg/day of folic
acid prior to conception and during the ﬁrst trimester [6]
and other studies have provided additional evidence of this
beneﬁcial eﬀect [1].
Folic acid is absorbed in the proximal part of the
small intestine and stored in the liver and CSF. About 4-52 ISRN Obstetrics and Gynecology
microgram is excreted daily in the urine. The mean dietary
intake of folic acid is about 0.1-0.2mg a day. Folic acid is
presentinfoodproductssuchasliver,kidney,nuts,yeast,and
greenvegetables.Itisreducedinthebodytotetrahydrofolate,
a coenzyme for many metabolic reactions including DNA
synthesis and amino acid conversion. Folate deﬁciency can
resultinmegaloblasticanemia.Therecommendeddailydose
o ff o l i ca c i dt op r e v e n tm e g a l o b l a s t i ca c i di np r e g n a n c yi s
0.2–0.5mg/day. Folic acid supplementation is well tolerated,
although gastrointestinal side eﬀects may occur. Folic acid
also plays an important role in the prevention of arterioscle-
rosis [5].
The Israel Ministry of Heath recommends a daily intake
of folic acid of 0.4mg/day three months before conception
and throughout the ﬁrst trimester. Women who previously
conceived an infant with NTD should take 0.4 mg/day of
folic acid throughout fertility and 4-5 mg/day beginning one
month before conception and throughout the ﬁrst trimester
[7].
In the present study we assessed the consumption of folic
acid for the prevention of NTDs among Jewish and Muslim
Bedouin women in southern Israel and analyzed possible
correlations with the recommendations of family physicians
and gynecologists.
The Jewish sector in Beer-Sheva is classiﬁed as low-
middle class. The Bedouin sector in southern Israel is
of a very low socioeconomic status, with many living in
small stone houses, wooden or tin huts, or even tents.
A considerable percentage of this population is supported
by welfare and has only a few years of formal education
[8].
2. Methods
2.1. Study Group. The study population included 65 preg-
nant Jewish women from the city of Beer-Sheva, 64 pregnant
Bedouin women from the Negev desert region of southern
Israel, 39 gynecologists (specialists and residents) from the
Soroka University Medical Center in Beer-Sheva and 60
family physicians (specialists and residents) from the Negev
region. The Helsinki Committee of the Soroka Medical
Center in Beer-Sheva and the Israel Ministry of Health
approved the study.
The interviews in the Jewish sector were held in three
clinics in Beer-Sheva that represent populations of diﬀerent
socioeconomic status, as determined by the Israel Ministry
of Health. The pregnant women were interviewed personally
by the ﬁrst author (EF) upon arrival for routine check-up at
the “Mother and Child Health Clinics” after consenting to
be interviewed and after it was clear that they had not been
interviewedpreviously.Womenvisitingtheclinicfortheﬁrst
time and women with a history of congenital anomaly in a
previous pregnancy were excluded.
The interviews in the Bedouin sector were held at a clinic
in a Bedouin village and in a Beer-Sheva clinic that serves
Bedouins living in rural areas outside established villages. In
those clinics we used a questionnaire that was translated into
Arabic with the aid of an interpreter.
Table 1: The demographic characteristics of the jewish and
bedouin women.
Variable Jews (n = 65) Bedouins
(n = 64) P
Age [N (%)]
17–20 2 (3) 7 (11)
NS 21–30 41 (63) 36 (57)
>30 22 (34) 20 (32)
Mean±SD 28.6±4.9 27.9±5.6
Present pregnancy
First to third 48 (74) 32 (50)
<.05 Fourth or more 17 (26) 32 (50)
Mean±SD 2.6±1.6 4.0±3.0
Children
0 26 (40) 14 (22)
<.05 1–3 34 (52) 29 (46)
4+ 5 (8) 20 (32)
Mean±SD 1.2±1.3 2.8±2.7
Education
None 1 (1.5) 14 (22)
<.0001 Elementary 1 (1.5) 20 (31)
High school 63 (97) 30 (47)
The doctors completed the questionnaires at work or
while attending continuing medical education courses at the
university.
2.2. The Study Tool. An anonymous questionnaire that
included questions on demographic background, knowledge
and use of folic acid was administered to the pregnant
women. A second anonymous questionnaire that included
questions on demographic background, knowledge, atti-
tudes, and recommendations regarding folic acid use was
given to the doctors.
2.3. Statistical Methods. The study data were organized with
the Excel software program and processed using the SSPS
statistical package. Group diﬀerences were compared by the
χ2 test and statistical signiﬁcance was set at P<. 05.
3. Results
3.1. Pregnant Women. The mean maternal age among 65
Jewish women was 28.6±4.9 years (range 20–39) and
27.9±5.6 among Bedouin women (range 17–40 years).
Four Bedouin women and nine Jewish women refused
to participate. The mean number of children per woman
was signiﬁcantly higher in the Bedouin sector. The women
from the Jewish sector were signiﬁcantly more educated
than the women from the Bedouin sector. Table 1 presents
the demographic background of the Jewish and Bedouin
women.ISRN Obstetrics and Gynecology 3
Table 2: Comparison of consumption of folic acid, by sector and
time during pregnancy.
Relation to pregnancy Bedouins N (%) Jews N (%) P
Before and during 4 (6.25) 7 (10.8)
<.05 Only during 56 (87.5) 44 (67.7)
Never 4 (6.25) 14 (21.5)
Fifty-one Jewish women (78.5%) reported taking folic
acid during pregnancy, but only seven (10.8%) began prior
to conception. Sixty Bedouin women (93.75%) reported
taking folic acid during pregnancy, but only four (6.25%)
began prior to conception (P<. 05) (Table 2). Only ﬁve
Jewish women (7.7%) and two Bedouin women (3.1%)
began taking folic acid three months before conception as
recommended by the Israel Ministry of Health. Sixty-one
Jewish women (94%) and all of the Bedouin women said
thattheyhadreceivedtheserecommendationsorknewabout
them. Seven of the ten Jewish women and three of the
four Bedouin women who refrained from taking folic acid
cited as the reason previous side eﬀects such as nausea,
weakness and dizziness that they attributed to it. Twenty-
eight Jewish women (43.1%) 18 Bedouin women (28.1%)
believed that folic acid could cause side eﬀects. Twenty three
Jewish women (35.4%) and four Bedouin women (6.3%)
knew that folic acid could prevent NTDs. Twenty of the
Bedouin women knew that taking folic acid could “help” the
fetus, but could not deﬁne speciﬁc health beneﬁts.
Only two Jewish women (3.1%) and 10 Bedouin women
(15.6%) had received and read the Ministry of Health
publication on prevention of NTDs, which is available at the
Mother and Child Clinics.
3.2. Doctors. The study was conducted among 60 fam-
ily physicians (54% women, mean age 38.9±7.6 years,
range 29–56) and 39 gynecologists (26% women, mean
age 39.5±8.5 years, range 29–59). Table 3 presents the
demographic background of thedoctors. Moregynecologists
than family physicians were department or unit heads,
while more family physicians were still in various stages of
professional training (residents).
Thirty-three gynecologists (87.9%) and 36 family physi-
cians (60%) claim to always recommend folic acid on
preconception examination. All the gynecologists and 55
family physicians (92%) reported that they almost always or
always recommend folic acid supplementation at this stage
(P<. 05). Thirty-three gynecologists (84%) and 44 family
physicians (73%) always recommend folic acid supplemen-
tation during pregnancy. Table 4 presents the physician
recommendations before and during pregnancy. Only 35 of
56 family physicians (62.5%) and 28 of 39 gynecologists
(71.8%)recommendedthecorrectdailydoseof0.4mg.Eight
family physicians (32.1%) and nine gynecologists (21.3%)
recommended a high daily dose of 5mg.
Seventeen of 37 gynecologists (45.9%) and 32 of 57
family physicians (56.1%) believe that more than 30% of the
women actually begin to take folic acid prior to conception.
Table 3: Comparison of gynecologists and family physicians.
Variable Gynecologists
(n = 39)
Family physicians
(n = 60) P
Sex
Male 28 (74) 26 (46) <.05
Female 10 (26) 31 (54)
Age (yrs)
<40 20 (62.5) 30 (64)
NS ≥ 40 12 (37.5) 17 (36)
Mean±SD 39.5±8.5 38.8±7.6
Years as physician
<10 19 (49) 30 (55)
NS ≥ 10 20 (51) 24 (45)
Mean±SD 13.7±11.3 11.2±7.9
Position
Department head 6 (15) 1 (2)
<.01 Other specialists 17 (43) 20 (33)
Resident 16 (42) 39 (65)
Table 4: Comparison of gynecologists and family physicians as to
recommendations to take folic acid prior to conception and during
pregnancy.
Extent of
recommendation
Gynecologists N
(%)
Family physicians
N (%) P
Prior to conception
Always 33 (87) 36 (60)
<.05 Almost always 5 (13) 19 (32)
Rarely — 5 (8)
During pregnancy
Always 33 (84) 44 (73)
NS Almost always 5 (13) 14 (23)
Rarely 1 (3) 2 (4)
4. Discussion
Folic acid supplementation before and during pregnancy is
an inexpensive, simple strategy that can signiﬁcantly reduce
the incidence of NTD, a very severe malformation. The
average lifetime cost of a baby with NTD is estimated
at about $294,000 [3]. There is evidence that folic acid
can also prevent other types of congenital anomalies [1].
Folic acid treatment before and during pregnancy is rec-
ommended by the Israel and the United States Ministries
of Health and by the American Academy of Pediatrics
[2, 9].
The results of the present study demonstrate that despite
the clear recommendations, only 10.8% of Jewish women
and 6.25% of Bedouin women take folic acid prior to
conception, although 78.5% of the Jewish women and
93.75% of the Bedouin women said they took folic acid at
some time during pregnancy.4 ISRN Obstetrics and Gynecology
The issue of folic acid supplementation prior to concep-
tionhasbeenstudiedinmanycountries.InBritishColumbia
[10] 49.4% of 1,004 took folic acid prior to conception.
In Puerto Rico [11] 31.5% of 479 women took folic acid
appropriately. In Ireland [12] 16% of 300 women took
folic acid prior to conception. In a previous Israeli study
conducted in 1999 [13] only 2.8% of 920 women took folic
acid before conception.
In the present study we found that although more
Bedouin women take folic acid during pregnancy than
Jewish women, fewer Bedouin women begin taking it prior
to conception. Since a relatively high rate of Jewish and
Bedouin women take folic acid during pregnancy, even if
inappropriately, the potential exists for better adherence to
recommendations with a concomitant reduction in the rate
of NTDs.
T h er a t eo fN T D si sa l m o s tf o u r f o l da m o n gB e d o u i n s
andothernon-JewishpopulationscomparedtoJews[4].The
reasons for this ﬁnding include consanguineous marriage
among Bedouins, diﬀerences in nutrition, and religious
prohibition of abortions. Special intervention plans should
be developed for each population based on its cultural and
socioeconomic characteristics.
A minority of women who did not take folic acid during
pregnancy despite recommendations cited fear of side eﬀects
that they attributed to its use during previous pregnancies.
Even the high dose of folic acid (5mg) prescribed by
32.1% of the family physicians and 23.1% of gynecologists
is unlikely to explain the reported side eﬀects, since these
side eﬀects are rare even at this higher dose. It is possible
that some of the women used this explanation as an excuse
because they were embarrassed that they did not take folic
acid.
There is a signiﬁcant diﬀerence between doctors’ reports
and the actual degree to which women took folic acid prior
to conception. All the gynecologists and 92% of the family
physicians in the study said that they always/almost always
recommend taking folic acid prior to conception, but only
10.8% of the Jewish women and 6.25% of the Bedouin
women reported taking folic acid at this stage. On the other
hand, there is correspondence between the doctors’ reports
of recommendations and the pregnant women’s reports of
folic acid use during pregnancy.
Despite the study’s small sample size the data demon-
strate that only a small minority of women use folic acid
appropriately. Since folic acid supplementation is the only
way to provide 4-5mg of folic acid daily it is important
to increase the public’s awareness of this requirement. An
intervention plan should include three basic strategies [14]:
diet, folic acid supplementation, and food fortiﬁcation.
According to a survey conducted in the year 2000 the mean
daily dietary intake of folic acid is 213.8±181.8 micrograms
among Jewish women and 302.0±226.9 micrograms among
Bedouin women (unpublished data). This diﬀerence may
be due to the relatively high intake of fresh vegetables by
Bedouins.
Our study demonstrates that only a small minority of the
women received and read the Ministry of Health’s publica-
tion on this issue. Other studies have reported that popular
newspapers and the electronic media are more eﬀective
than printed material disseminated by health authorities
[9].
5. Conclusions
It is important to train health system workers in the
community to recommend folic acid before, and not only
after, conception. It is important for physicians to encourage
a preconception examination in which counseling and rec-
ommendations for folic acid supplementation are provided.
Special attention should be given to family physicians since,
according to the results of the present study, only 60% always
recommend folic acid prior to conception.
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